Molecular Basis for Altered Natural Killer Cells in Systemic Sclerosis associated-Interstitial Lung Disease

NIH RePORTER · NIH · P50 · $147,840 · view on reporter.nih.gov ↗

Abstract

Cristina Padilla, MD NIAMS Diversity Supplement 2024-2026 The Molecular Basis of Altered Natural Kill Cells in Systemic Sclerosis-associated Interstitial Lung Disease Project Summary An activated, cytotoxic natural killer (NK) cell population was identified in scleroderma-associated interstitial lung disease (SSc-ILD) that showed upregulation in several genes, including Granzyme B, Amphiregulin, and Interferon-gamma. Because the genes are suspected to play a critical role in the pathogenic effects in the lungs, this project will use single cell technologies, including single cell ATAC sequencing (scATAC-seq) and Multiome-seq (combined single nuclear RNA-seq and snATAC-seq), to understand how these genes are regulated. By assessing the state of open chromatin across the genome using computational analysis, transcription factors (TF) can be predicted that are regulating this process. Experiments will be utilized to better understand the pathways that cause NK cell activation in SSc-ILD by comparing TF regulating SSc-ILD NK cells from lung with TF activated by cytokine simulation in vitro of NK cells purified from blood and healthy lungs. We hypothesize that open chromatin in NK cells will implicate key transcription factors (TFs) that regulate NK cell activation in SSc-ILD lungs, and that alteration of these TFs drive expression of AREG, IFNG and GZMB, as well as other key genes in their aberrant pathway of differentiation.

Key facts

NIH application ID
11087300
Project number
3P50AR080612-03S1
Recipient
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
Principal Investigator
ROBERT A. LAFYATIS
Activity code
P50
Funding institute
NIH
Fiscal year
2024
Award amount
$147,840
Award type
3
Project period
2024-09-20 → 2026-08-31